Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @GuardantHealth
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @GuardantHealth
-
And he will be hiring! Click here to read more about Kumud: http://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-appoints-high-tech-veteran-kumud-kalia-chief … Click here to see some of our open Engineering and IT roles: https://guardanthealth.com/careers/jobs/#engineering …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Kumud’s leadership and his experience across the technology, cybersecurity, telecommunications and finance sectors will be a great asset as we scale up our data infrastructure and prepare for our next phase of growth.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are thrilled to announce that
@Kumud Kalia has joined Guardant as our Chief Information Officer. Kumud will lead Guardant’s enterprise application, information technology, and security teams.pic.twitter.com/mJWRnlpe5m
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are excited to work with
@Amgen to develop the Guardant360 companion diagnostic test for AMG 510, an investigational oral therapy that inhibits KRAS G12C mutant protein.http://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-announces-collaboration-amgen-develop-global …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The potential to target KRAS G12C, a mutation that was once thought to be undruggable, represents a potentially major therapeutic advancement.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re excited to announce the COBRA study with
@NRGOnc to validate the clinical utility of our molecular residual disease assay as a diagnostic biomarker for selecting which patients with stage II colon cancer need adjuvant chemotherapy.http://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-and-nrg-oncology-initiate-randomized-trial …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This is an important new development for Medicare patients with advanced cancer and for Guardant Health. Medicare will expand coverage for Guardant360 across the vast majority of solid tumor cancers. Read more:http://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-receives-expanded-medicare-coverage-guardant360 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New data presented at
#SABCS19 shows Guardant360 effectively guides precision oncology treatment in metastatic breast cancer patients.https://twitter.com/ICR_London/status/1205178077841633287 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New study shows only 40 percent of patients with metastatic colon cancer receive guideline-recommended biomarker testing:http://bit.ly/2LHcU4E
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We were honored to accept the
@CAlifesciences Outstanding Product, Medical Device/Diagnostic Award at the 2019#CLSAPantheon Ceremony on behalf of@Guardant360. Thank you for recognizing our work.https://twitter.com/CALifeSciences/status/1195559279165497345 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Guardant Health proslijedio/la je Tweet
Patient and caregiver non-profit organisations are now invited to submit proposals to Initiatives in Lung Cancer Care (ILC2), a grant opportunity for projects that can improve quality of care and the patient experience. Learn more here http://bit.ly/33j6tLP
#LCAM#LungAmbitionpic.twitter.com/SRsqixuqGmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are proud to initiate the ECLIPSE trial, a 10,000-patient, pivotal study for our LUNAR-2 blood test for colorectal cancer screening. Read more:http://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-initiates-eclipse-pivotal-study-its-lunar-2 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapyhttp://bit.ly/2mEX8hh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
2.1 million people are diagnosed w/
#lungcancer each year globally. Yesterday, we joined@AstraZeneca,@IASLC and@globalungcancer to announce the#LungAmbition Alliance, to one day end the disease as a cause of death: http://www.lungambitionalliance.org/#lcsmpic.twitter.com/lJtfSkIoT4Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're excited to see the Guardant360 assay designated for the FDA's Expedited Access Pathway as we prepare our submission to the FDA later this year.http://prn.to/2o7XfPf
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Important new research from
@UChicagoMed about the genomic heterogeneity of gastroesophageal adenocarcinoma.http://prn.to/2jsMHM1Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Guardant Health proslijedio/la je Tweet
Excited to discuss early cancer detection and precision medicine at the
@ClevelandClinic#MIS2017.pic.twitter.com/yp1MkNTDWh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to our cofounders
@Helmy_L2K and AmirAli Talasaz for making @FortuneMagazines's 40 under 40 list! http://for.tn/2i915YwHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Guardant Health proslijedio/la je Tweet
.
@myESMO abstr titles are out! Excited to be presenting results from 30,000 pts examined w ctDNA!@GuardantHealth@cityofhopepic.twitter.com/JGJg4SL5Jd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.